The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.
 
Francois Clement Bidard
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; Daiichi-Sankyo; Exact Sciences; GE Healthcare; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche; SAGA Diagnostics
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Menarini Group; Novartis; Pfizer
Research Funding - GE Healthcare (Inst); Menarini Silicon Biosystems (Inst); Merck KGaA (Inst); MSD (Inst); Novartis (Inst); Personalis (Inst); Pfizer (Inst); Prolynx (Inst); SAGA Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - ESR1 & MSI detection techniques (patents) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi-Sankyo; Novartis; Pfizer; Roche
 
Frederique Berger
No Relationships to Disclose
 
Monica Arnedos
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer
 
Marie-Ange Mouret-Reynier
No Relationships to Disclose
 
Olivier Tredan
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Pfizer; Pierre Fabre; Roche; Sandoz-Novartis; Stemline Therapeutics; Veracyte
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche
 
Renaud Sabatier
Honoraria - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Novartis
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD Oncology
 
William Jacot
Honoraria - AstraZeneca; BMSi; Daiichi Sankyo Europe GmbH; Eisai; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; BMSi; Daiichi Sankyo Europe GmbH; Eisai; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche; Seagen
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/Daiichi Sankyo (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Chugai Pharma; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Novartis; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
 
Vincent Massard
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Gilead Sciences; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre
Travel, Accommodations, Expenses - Advanced Accelerator Applications; AstraZeneca; Gilead Sciences; Janssen Oncology; Novartis; Pfizer
 
Thibault De La Motte Rouge
Honoraria - AstraZeneca; Gilead Sciences; GlaxoSmithKline; MSD Oncology; Mylan; Pfizer; Roche/Genentech; Sanofi; Tesaro
Consulting or Advisory Role - AstraZeneca; Eisai; Eisai; Gilead Sciences; GlaxoSmithKline; MSD Oncology (Inst); Mylan; Pfizer; Roche; Sanofi; Tesaro
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer; Roche
 
Joseph Gligorov
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Eva Pharma; Exact Sciences; Gilead Sciences; Lilly; Menarini; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; Exact Sciences; GE Healthcare; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eva Pharma; Exact Sciences; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer; Seagen
 
Luis Teixeira
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly
Research Funding - Novartis; Novartis (Inst)
Travel, Accommodations, Expenses - Gilead Sciences
 
Frédéric Fiteni
Consulting or Advisory Role - AstraZeneca; Daiishi-Serono; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Pfizer
 
Julien Grenier
Travel, Accommodations, Expenses - AstraZeneca; Eisai
 
Florence Dalenc
Consulting or Advisory Role - fizer, Seagan, Gilead, Astra Zeneca, Diiachi, Novartis (Inst); fizer, Seagan, Gilead, Astra Zeneca, Diiachi, Novartis (Inst)
Travel, Accommodations, Expenses - Gilead and Novartis (Inst)
 
Irène Buvat
Research Funding - GE Healthcare (Inst); Siemens Healthineers (Inst)
Patents, Royalties, Other Intellectual Property - Pending patent EP N°22 305 747.2 "METHOD FOR PROCESSING 3D IMAGING DATA AND ASSISTING WITH PROGNOSIS OF CANCER"
 
Fatima Mechta-Grigoriou
Research Funding - Roche (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent: Methods for the treatment of fibrotic related diseases Application number: EP23306606.7 Djerroudi L, Vincent-Salomon A. and Mechta-Grigoriou F (Inst); Patent: New populations of fibroblasts and macrophages as prognosis markers for detection of fibroblasts associated diseases Application number: EP23306326.2 Cohen C and Mechta-Grigoriou F (Inst)
Travel, Accommodations, Expenses - 10X Genomics
 
Nicolas Kiavue
Other Relationship - Grunenthal (Inst)